{"id":701810,"date":"2022-10-27T08:16:43","date_gmt":"2022-10-27T12:16:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/"},"modified":"2022-10-27T08:16:43","modified_gmt":"2022-10-27T12:16:43","slug":"bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/","title":{"rendered":"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Oct.  27, 2022  (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 3, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide business highlights.<\/p>\n<p>\n        <strong>Conference Call and Webcast Information<\/strong><br \/>\n        <br \/>Date: November 3, 2022<br \/>Time: 4:30 p.m. ET<br \/>Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K0LJYwD-k7PV_dGck6q27BMJ2_kBnIt8VzFqe1laoAIeW0emOQQepi7Vc3Xty0Ld1UN28TF-sMMfCg9N4r06t4mBs4kvjiGPSfuLew-z4TSk1n3Oj3MS1wi2s7N0_6mUfuoMI-0RNjQSX3XS6--hQUzbgDFjdKL8k6tJNnuJWGj6pmvkGYoryVxHOGh9vfIB\" rel=\"nofollow noopener\" target=\"_blank\">BioAtla Third Quarter 2022 Earnings Conference Call<\/a><br \/>Dial-in Numbers: (844) 826-3035 (domestic) or (412) 317-5195 (international)<br \/>Conference ID: 10171336<\/p>\n<p>The press release with the financial results will be accessible prior to the conference call through \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w3jl5xGYQR2RstecNs4d3NETQzQezOPheyEO0v1v2bg-wWm_u1B6IBNhJOMo7mXKb61h_6kCyWiRvNGSzbLwb4efXeOuGVABwwq1A9wuKVcgziYY_5fHELJIG64SLtge\" rel=\"nofollow noopener\" target=\"_blank\">News Releases<\/a>\u201d in the News &amp; Events section of the company\u2019s website. A replay of the call will also be available through \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C7zYwLxxPa1KzQL6_B1h9_t1H9VRcFjmK_8XEMlzxn_hQC7s4Wv7bXQ6QECtsenyi7k7ZT214vmJJt4ct8KPqRnGn6u6g5ERz4FjeDEu7RM=\" rel=\"nofollow noopener\" target=\"_blank\">Events &amp; Presentations<\/a>\u201d in the Investors section of the company\u2019s website.<\/p>\n<p>\n        <strong>About BioAtla, Inc.<\/strong><br \/>\n        <br \/>BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal antibody and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with more than 600 patents, more than 350 of which are issued. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing in the United States, mecbotamab vedotin, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 1 stage CAB-CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DdH2a4RKVuU-iQQgiKqD0HVanm-ZAmB9I6ZOmTcSubK5LvXR68yBxFxoPIpFJPdgApoXZlAXJpVhoKUylKGeTw==\" rel=\"nofollow noopener\" target=\"_blank\">www.bioatla.com<\/a>.<\/p>\n<p>\n        <strong>Internal Contact:<\/strong><br \/>\n        <br \/>Richard Waldron<br \/>Chief Financial Officer<br \/>BioAtla, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ngWMqRvV6q-U_FNNr5pi-xRBdj8ApBll895ePZzO9MX4W2tdyX2kihClEAgfNYHPa_wZDc6ZrW43KFkpqgLj90_Rd0RbxqOqers9Tq3cwXw=\" rel=\"nofollow noopener\" target=\"_blank\">rwaldron@bioatla.com<\/a><br \/>858.356.8945<\/p>\n<p>\n        <strong>External Contact:<\/strong><br \/>\n        <br \/>Bruce Mackle<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dW9ITxvkyaksXd09MIY30Zd67Jjbe2z_oJnT5Gj-_76pjz00YbDidANWZ2m4guIiGnoPNfndna69SOEupXwCJeuFGw1wUzD17x25ZpDoERupQ8sB2xcevzeCUfB1YzsZ\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDcwMmU5NjMtOGY0NC00OTU0LTk1OTMtZmY3MmRjZjNjZTViLTEyMDE2ODg=\/tiny\/BioAtla-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 3, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide business highlights. Conference Call and Webcast Information Date: November 3, 2022Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2022 Earnings Conference CallDial-in Numbers: (844) 826-3035 (domestic) or (412) 317-5195 (international)Conference ID: 10171336 The press release with the financial results will be accessible prior to the conference call through \u201cNews Releases\u201d in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701810","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 3, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide business highlights. Conference Call and Webcast Information Date: November 3, 2022Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2022 Earnings Conference CallDial-in Numbers: (844) 826-3035 (domestic) or (412) 317-5195 (international)Conference ID: 10171336 The press release with the financial results will be accessible prior to the conference call through \u201cNews Releases\u201d in &hellip; Continue reading &quot;BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T12:16:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022\",\"datePublished\":\"2022-10-27T12:16:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/\"},\"wordCount\":385,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/\",\"name\":\"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=\",\"datePublished\":\"2022-10-27T12:16:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/","og_locale":"en_US","og_type":"article","og_title":"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022 - Market Newsdesk","og_description":"SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 3, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide business highlights. Conference Call and Webcast Information Date: November 3, 2022Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2022 Earnings Conference CallDial-in Numbers: (844) 826-3035 (domestic) or (412) 317-5195 (international)Conference ID: 10171336 The press release with the financial results will be accessible prior to the conference call through \u201cNews Releases\u201d in &hellip; Continue reading \"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T12:16:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022","datePublished":"2022-10-27T12:16:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/"},"wordCount":385,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/","name":"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=","datePublished":"2022-10-27T12:16:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MTMzNSM1MjIwOTc1IzIxOTAxMzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioatla-to-announce-third-quarter-2022-financial-results-and-provide-business-highlights-on-november-3-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701810"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701810\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}